title: Should rosuvastatin be withdrawn from the market?
authors.forename: Stefan R
authors.initials: SR
authors.lastname: Florentinus
authors.forename: Eibert R
authors.initials: ER
authors.lastname: Heerdink
authors.forename: Olaf H
authors.initials: OH
authors.lastname: Klungel
authors.forename: Anthonius
authors.initials: A
authors.lastname: de Boer
mesh_terms: D017277:Drug Approval; D004363:Drug Utilization; D005464:Fluorobenzenes / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D009426:Netherlands; D011358:Product Surveillance, Postmarketing; D011743:Pyrimidines / Q000009:adverse effects* / Q000627:therapeutic use; D000068718:Rosuvastatin Calcium; D013449:Sulfonamides / Q000009:adverse effects* / Q000627:therapeutic use
chemical_list: D005464:Fluorobenzenes; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D011743:Pyrimidines; D013449:Sulfonamides; D000068718:Rosuvastatin Calcium